Jennison Associates
TARS icon

Jennison Associates’s Tarsus Pharmaceuticals TARS Stock Holding History

Jennison Associates’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105M Sell
1,663,655
-48,469
-3% -$3.1M 0.06% 161
2026
Q1 		$120M Sell
1,712,124
-517,945
-23% -$36.2M 0.08% 111
2025
Q4 		$183M Sell
2,230,069
-374,511
-14% -$28M 0.11% 78
2025
Q3 		$155M Buy
2,604,580
+136,582
+6% +$6.72M 0.09% 94
2025
Q2 		$100M Sell
2,467,998
-24,642
-1% -$1.11M 0.06% 133
2025
Q1 		$128M Sell
2,492,640
-7,492
-0.3% -$370K 0.09% 112
2024
Q4 		$138M Buy
2,500,132
+321,552
+15% +$14.6M 0.08% 107
2024
Q3 		$71.7M Buy
2,178,580
+698,712
+47% +$19.6M 0.04% 168
2024
Q2 		$40.2M Buy
1,479,868
+148,930
+11% +$5.01M 0.03% 247
2024
Q1 		$48.4M Buy
+1,330,938
New +$39.1M 0.03% 222

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Jennison Associates's TARS Position: Q2 2026 in Review

Jennison Associates reduced its Tarsus Pharmaceuticals (TARS) stake by 2.8% in Q2 2026, selling an estimated $3.1M and leaving 1,663,655 shares worth $105M. The position accounts for 0.06% of the portfolio, ranked #161.

Jennison Associates first reported a position in TARS in Q1 2024 and has held it in 10 quarters since. The position peaked at $183M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Jennison Associates held 1,663,655 shares of Tarsus Pharmaceuticals worth $105M as of Q2 2026.
  • Jennison Associates sold 48,469 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $3.1M.
  • Tarsus Pharmaceuticals made up 0.06% of Jennison Associates's portfolio in Q2 2026, its #161 holding.
  • Jennison Associates first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Jennison Associates's Tarsus Pharmaceuticals position peaked at $183M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.